Search results for "Mono"

showing 10 items of 6843 documents

Production and characterization of a monoclonal antibody to the trichothecene mycotoxin diacetoxyscirpenol.

1988

A monoclonal antibody was obtained by the fusion of mouse myeloma cells with splenocytes isolated from Balb/c mice, which had been immunized with diacetoxyscirpenol-hemiglutarate (DAS-hemiglutarate) and verrucarol-hemiglutarates covalently bound to ethylenediamine-modified bovine serum albumin. The anti-DAS-antibody that could be induced was of the IgM type with kappa-chains. The titer of the monoclonal anti-DAS-antibody in ascites fluid obtained from mice injected the selected cell line was much higher than those of conventional antisera. An enzyme-linked immunosorbent assay based on the competitive binding principle in which the antibody was applied had a sensitivity of 1 ng DAS per assay…

medicine.drug_classTrichotheceneEnzyme-Linked Immunosorbent AssayCross ReactionsMonoclonal antibodyBiochemistryDiacetoxyscirpenolchemistry.chemical_compoundMicemedicineAnimalsBovine serum albuminAntiserumMice Inbred BALB CbiologyAntibodies MonoclonalMycotoxinsMolecular biologyTiterchemistryMonoclonalbiology.proteinFemaleAntibodyTrichothecenesSesquiterpenesBiological chemistry Hoppe-Seyler
researchProduct

Generation of multifunctional murine monoclonal antibodies specifically directed to the VP1unique region protein of human parvovirus B19.

2007

Little is known about the VP1unique region (VP1u), a part of one major capsid protein of human parvovirus B19 (B19), concerning its involvement in viral replication and infection cycle. Showing a phospholipase A2 (PLA2)-like activity, which is discussed to be necessary for viral release from host cell, its precise function remains unclear. The purpose of this study was to generate multifunctional monoclonal antibodies (mabs) for different applications that may be useful in investigating VP1u's relevance. To establish antiVP1u antibodies, spleen cells from Balb/c mice immunized with purified recombinant viral protein were used for generating antibody-producing hybridoma cell lines. Usability…

medicine.drug_classViral proteinPhospholipase A2 InhibitorsvirusesImmunologySpleenImmunofluorescenceMonoclonal antibodymedicine.disease_causeAntibodies Virallaw.inventionMicelawmedicineParvovirus B19 HumanImmunology and AllergyAnimalsHumansMice Inbred BALB Cbiologymedicine.diagnostic_testAntibodies MonoclonalHematologyVirologyMolecular biologyRecombinant ProteinsPhospholipases A2medicine.anatomical_structureCapsidViral replicationbiology.proteinRecombinant DNACapsid ProteinsAntibodyImmunobiology
researchProduct

Modulation of melanoma-associated antigens by monoclonal antibodies as visualized by radioimmunoelectron microscopy and radioantibody binding assay

1987

There is a wealth of information about monoclonal antibody (MAb) specificity and function on fixed tissues, yet little is known about formation and release of antigen-antibody complexes and their functional behavior in vivo. We analyzed the pathway of radiolabeled MAbs directed against melanoma-associated antigens by radioimmunoelectron microscopy (RIEM) on metabolically active cells of the melanoma cell lines SK-MEL-28, MeWo and Colo 38 at different time intervals. In parallel, binding and release of MAbs were investigated by the radioantibody binding assay (RBA). Both procedures gave essentially concordant results. Preferentially stable binding of immune complexes (ICs) to the cell surfac…

medicine.drug_classmedia_common.quotation_subjectMelanoma ExperimentalRadioimmunoassayCoated vesicleAntigen-Antibody ComplexDermatologyBiologyEndocytosisMonoclonal antibodyCell LineCell membranemedicineInternalizationmedia_commonLigand binding assayAntibodies MonoclonalGeneral MedicineVirologyMolecular biologyEndocytosisMicroscopy Electronmedicine.anatomical_structureCytoplasmAutoradiographyAntigenic ModulationBinding Sites AntibodyArchives of Dermatological Research
researchProduct

Humoral immunotherapy of multiple myeloma: perspectives and perplexities

2010

IMPORTANCE OF THE FIELDS Multiple myeloma (MM) is a hematological malignancy still remaining incurable despite the various therapies available, mainly because of the high fraction of refractory/relapsing cases. Therefore, the development of novel therapeutic approaches is urgently needed to overcome conventional treatment resistance. AREAS COVERED IN THIS REVIEW: In the era of targeted therapies, treatments combining a high specificity for neoplastic cells and the capability to interfere with environmental signals should be regarded as the weapons of choice. Monoclonal antibody (mAb)-based humoral immunotherapy could satisfy both these requirements when applied to MM. Indeed, many of the mo…

medicine.drug_classmedicine.medical_treatmentClinical BiochemistryCD38Monoclonal antibodyAntigens NeoplasmDrug DiscoverymedicineAnimalsHumansMultiple myelomamultiple myeloma; immunotherapyPharmacologyCD40biologybusiness.industryConventional treatmentAntibodies MonoclonalImmunotherapymedicine.diseaseImmunity Humoralmultiple myelomamultiple myeloma humoral immunotherapyHematological malignancyImmunologyMolecular targetsbiology.proteinimmunotherapybusiness
researchProduct

Interleukin-15, as Interferon-gamma, Induces the Killing of Leishmania infantum in Phorbol-Myristate-Acetate-Activated Macrophages Increasing Interle…

2004

The potential leishmanicidal activity of interleukin-15 (IL-15) was examined while priming with the cytokine phorbol-myristate-acetate (PMA)-activated macrophages and infecting them with Leishmania infantum parasites. The activation of macrophage cultures with IL-15 determined a significant anti-leishmanial activity, comparable with that induced by interferon-gamma (IFN-gamma). The killing of Leishmania in macrophages primed with IL-15, as well as with IFN-gamma, was followed by an increase in the IL-12 synthesis. The neutralization of IL-15 or IFN-gamma, by specific monoclonal antibodies (MoAb) caused a significant reduction in leishmanicidal activity. Furthermore, in PMA-activated macroph…

medicine.drug_classmedicine.medical_treatmentImmunologyMonoclonal antibodyNeutralizationMicrobiologyInterferon-gammaMicemedicineAnimalsInterferon gammaLeishmania infantumInterleukin-15biologyActivator (genetics)MacrophagesGeneral Medicinebiology.organism_classificationInterleukin-12CytokineInterleukin 15Interleukin 12Leishmaniasis VisceralTetradecanoylphorbol AcetateLeishmania infantummedicine.drugScandinavian Journal of Immunology
researchProduct

Identification of markers for the selection of patients undergoing renal cell carcinoma-specific immunotherapy

2003

Renal cell carcinoma (RCC) represents the most common malignant tumor in the kidney and is resistant to conventional therapies. The diagnosis of RCC is often delayed leading to progression and metastatic spread of the disease. Thus, validated markers for the early detection of the disease as well as selection of patients undergoing specific therapy is urgently needed. Using treatment with the monoclonal antibody (mAb) G250 as a model, proteome-based strategies were implemented for the identification of markers which may allow the discrimination between responders and nonresponders prior to application of G250-mediated immunotherapy. Flow cytometry revealed G250 surface expression in approxi…

medicine.drug_classmedicine.medical_treatmentMonoclonal antibodyBiochemistryMass SpectrometryFlow cytometrySequence Analysis ProteinRenal cell carcinomaCell Line TumorBiomarkers TumormedicineCarcinomaHumansElectrophoresis Gel Two-DimensionalCarcinoma Renal CellMolecular Biologybiologymedicine.diagnostic_testAntibodies MonoclonalProteinsImmunotherapyFlow Cytometrymedicine.diseaseKidney NeoplasmsImmunologyProteomebiology.proteinCancer researchImmunohistochemistryImmunotherapyAntibodyPROTEOMICS
researchProduct

Injection of Donor-Derived OX62+ Splenic Dendritic Cells With Anti-CD4 Monoclonal Antibody Generates CD4+CD25+FOXP3+ Regulatory T Cells That Prolong …

2009

Abstract Objective To examine in a rat model the ability of donor dendritic cells and anti-CD4 monoclonal antibody (mAb) to generate donor-specific CD4+CD25+ regulatory T cells (Tregs) and to evaluate the capacity of these Tregs to prolong skin allograft survival and abrogate the production of donor-specific antibodies after skin grafting. Materials and Methods OX62+ (nonplasmacytoid) splenic dendritic cells were isolated from Fischer rats using magnetic beads and injected (2 × 10 6 ) into Lewis rat recipients with or without treatment with a nondepleting anti-CD4 (W3/25) mAb. After 4 weeks, splenic CD4+CD25+FOXP3+ T cells were harvested using magnetic beads from conditioned animals and inj…

medicine.drug_classmedicine.medical_treatmentSpleenMonoclonal antibodyT-Lymphocytes RegulatoryIsoantibodiesRats Inbred BNAnimalsTransplantation HomologousMedicineIL-2 receptorAntigen-presenting cellTransplantationbusiness.industryGraft SurvivalInterleukin-2 Receptor alpha SubunitAntibodies MonoclonalForkhead Transcription FactorsDendritic CellsSkin TransplantationDendritic cellDonor LymphocytesRats Inbred F344RatsTransplantationmedicine.anatomical_structureRats Inbred LewCD4 AntigensModels AnimalImmunologySkin graftingSurgerybusinessTransplantation Proceedings
researchProduct

A Synthetic Glycopeptide Vaccine for the Induction of a Monoclonal Antibody that Differentiates between Normal and Tumor Mammary Cells and Enables th…

2015

In studies within the realm of cancer immunotherapy, the synthesis of exactly specified tumor-associated glycopeptide antigens is shown to be a key strategy for obtaining a highly selective biological reagent, that is, a monoclonal antibody that completely differentiates between tumor and normal epithelial cells and specifically marks the tumor cells in pancreas tumors. Mucin MUC1, which is overexpressed in many prevalent cancers, was identified as a promising target for this strategy. Tumor-associated MUC1 differs significantly from that expressed by normal cells, in particular by altered glycosylation. Structurally defined tumor-associated MUC1 cannot be isolated from tumor cells. We synt…

medicine.drug_classmedicine.medical_treatmentTumor M2-PKBreast NeoplasmsBiology010402 general chemistryMonoclonal antibody01 natural sciencesCancer VaccinesCatalysisCancer immunotherapyAntigenPancreatic tumorPancreatic cancermedicineHumansBreastMUC1010405 organic chemistryMucinGlycopeptidesAntibodies MonoclonalGeneral Chemistrymedicine.diseaseMolecular biology0104 chemical sciencesPancreatic NeoplasmsFemaleAngewandte Chemie (International ed. in English)
researchProduct

Screening for inhibitors of HIV gp120-CD4 binding using an enzyme-linked immunoabsorbent assay.

1993

Binding of the HIV-1 major viral surface glycoprotein, gp120, to the major cell receptor, CD4, is essential for HIV infection of the target cell and syncytium formation. An enzyme-linked immunoassay using solid phase CD4 was used to quantitate the binding of HIV-1 gp120 to CD4, and to assess the activity and mechanism of action of putative inhibitors of that reaction. Monoclonal antibodies to the gp120 binding site on CD4 (e.g., Leu3a) blocked gp120 binding, while monoclonal antibodies to other portions of CD4 (e.g. OKT4) did not. Both aurintricarboxylic acid and sulfonated polysaccharides (e.g., dextran sulfate) blocked CD4-gp120 interactions by binding to the CD4 component. Human polyclon…

medicine.drug_classvirusesEnzyme-Linked Immunosorbent AssayHIV Envelope Protein gp120Monoclonal antibodyAntiviral Agentschemistry.chemical_compoundPolysaccharidesVirologyLectinsAurintricarboxylic acidmedicineGlycoproteinschemistry.chemical_classificationbiologyLigand binding assayvirus diseasesLectinReproducibility of ResultsMolecular biologyRecombinant ProteinsEnzymechemistryMechanism of actionPolyclonal antibodiesCD4 Antigensbiology.proteinHIV-1medicine.symptomAntibodyJournal of virological methods
researchProduct

Short synthetic CDR-peptides forming the antibody combining site of the monoclonal antibody against RNA bacteriophage fr neutralize the phage activit…

1996

The construction of a mouse hybridoma FRS2 secreting neutralizing monoclonal antibody specific for RNA bacteriophages fr, MS2 and GA is reported. The genes encoding the variable domains of the monoclonal antibody FRS2 heavy and light chains were cloned and sequenced and the corresponding complementarity determining region (CDR) peptides were chemically synthesized. The CDR-peptides were tested for their ability to neutralize the activity of RNA phage fr and related RNA phages MS2 and GA. The CDR-derived peptides H2, L2 and L3 interacted with the fr phage particles and neutralized fr phage activity. Two of these peptides-H2 and L3 also had the ability to neutralize partly the activity of rel…

medicine.drug_classvirusesImmunologyMolecular Sequence DataImmunoglobulin Variable Regionchemical and pharmacologic phenomenaEnzyme-Linked Immunosorbent AssayComplementarity determining regionRNA PhagesMonoclonal antibodyBacteriophageMiceAntigenNeutralization TestsBacteriophage MS2medicineImmunology and AllergyAnimalsAmino Acid SequenceCloning MolecularMicroscopy ImmunoelectronMice Inbred BALB CbiologyBase SequenceRNAAntibodies MonoclonalGeneral MedicineRNA Phagesbiology.organism_classificationMolecular biologyPeptide Fragmentsbiology.proteinAntibodyHuman antibodies and hybridomas
researchProduct